Programmed cell death ligand 1 expression in cytologic and surgical non–small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations
| Autor: | Konstantin Shilo, Ping Mei, Lai Wei, Zaibo Li, Rulong Shen, Dena Tonkovich |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Cancer Research Pathology medicine.medical_specialty Lung Neoplasms Biopsy Fine-Needle 030209 endocrinology & metabolism Pembrolizumab medicine.disease_cause B7-H1 Antigen Article Proto-Oncogene Proteins p21(ras) 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Carcinoma Non-Small-Cell Lung Cytology Biopsy Biomarkers Tumor Carcinoma Humans Medicine Clinical significance Pneumonectomy Lung Aged Aged 80 and over medicine.diagnostic_test business.industry Patient Selection Middle Aged medicine.disease medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Mutation Immunohistochemistry Female KRAS business |
| Zdroj: | Cancer Cytopathology. 127:447-457 |
| ISSN: | 1934-6638 1934-662X |
| DOI: | 10.1002/cncy.22140 |
| Popis: | BACKGROUND: Programmed cell death ligand 1 (PD-L1) expression by the 22C3 pharmDx companion assay has been validated in surgical specimens to support pembrolizumab treatment decisions for patients with non–small cell lung carcinoma (NSCLC). The aims of this study were 1) to assess the adequacy of cytologic specimens for PD-L1 evaluation and 2) to explore correlations of PD-L1 expression with clinicopathologic and molecular features. METHODS: The study cohort included 100 cytology specimens (fluid [n = 28] and fine-needle aspiration [n = 72]) and 165 surgical specimens (biopsy [n = 138] and resection [n = 27]). The PD-L1 immunohistochemistry 22C3 assay and staining assessment were performed according to the manufacturer’s instructions. PD-L1 expression was correlated with patients’ demographics, pathologic characteristics, and molecular alterations. RESULTS: One hundred forty-two specimens (53.6%) were positive for PD-L1 expression (≥1%). No statistically significant difference in PD-L1 expression was identified between cytologic (56.0%) and surgical specimens (52.1%). Seventy-four of 190 tested cases (38.9%) had genetic alterations. PD-L1 positivity was significantly more prevalent in cases with genetic alterations than in cases without genetic alterations. Furthermore, both PD-L1 positivity and high PD-L1 expression (≥50%) had statistically significant associations with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. PD-L1 expression had no significant association with histologic phenotypes or other clinicopathologic features. CONCLUSIONS: The data indicate that cytologic specimens are comparable to surgical specimens for PD-L1 evaluation. The association of PD-L1 expression with KRAS mutations may have clinical relevance in selecting patients with NSCLC for immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text